Page last updated: 2024-08-26

fulvestrant and Cystadenocarcinoma, Serous

fulvestrant has been researched along with Cystadenocarcinoma, Serous in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Hossain, MM; Ishibashi, T; Ishikawa, M; Kanno, K; Kyo, S; Nakayama, K; Nakayama, S; Otsuki, Y; Razia, S; Sato, S; Shanta, K; Yamashita, H	1

Other Studies

1 other study(ies) available for fulvestrant and Cystadenocarcinoma, Serous

Article	Year
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines. Current oncology (Toronto, Ont.), 2022, 06-01, Volume: 29, Issue:6 Topics: Cell Line; Cystadenocarcinoma, Serous; Female; Fulvestrant; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Phosphatidylinositol 3-Kinases; Receptors, Estrogen	2022

Article

Year

Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.

Current oncology (Toronto, Ont.), 2022, 06-01, Volume: 29, Issue:6

Topics: Cell Line; Cystadenocarcinoma, Serous; Female; Fulvestrant; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Phosphatidylinositol 3-Kinases; Receptors, Estrogen

2022